Vizsgálati helyszín
Beijing
Beijing, 100036, KínaMég nincs intézményhez kötve
- 16futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz8 vizsgálat
- Lezárult7 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- GlaxoSmithKline24 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· 2. fázis· GlaxoSmithKline· Forrás
Contact: Zhaohui Tong (principal investigator)
Toboroz
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· 3. fázis· GlaxoSmithKline· Forrás
Contact: Yingxiang lin (principal investigator)
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Contact: Yingxiang lin (principal investigator)
Toboroz
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· 3. fázis· GlaxoSmithKline· Forrás
Contact: Hongmei Jing (principal investigator)
Toboroz
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606· 3. fázis· GlaxoSmithKline· Forrás
Contact: juan meng (principal investigator)
Fut, nem toboroz
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Contact: Yan Sun (principal investigator)
Toboroz
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· 2/3. fázis· GlaxoSmithKline· Forrás
Contact: Yuewu Lu (principal investigator)
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Contact: Lin Shen (principal investigator)
Fut, nem toboroz
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· 3. fázis· GlaxoSmithKline· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek